Skip Navigation

U.S. Department of Health and Human Services

Office of Minority Health

Office of Minority Health (OMH) Logo

Print Page A A A
En Español Newsroom Contact Us

Eliminating the Public Health Problem of Hepatitis B and C in the United States

On March 28, 2017, the National Academies of Sciences, Engineering, and Medicine released the second phase of a report on eliminating viral hepatitis in the United States. The report, Eliminating the Public Health Problem of Hepatitis B and C in the United States Exit Disclaimer, provides a U.S. strategy for eliminating hepatitis B and hepatitis C virus infection and the disease and mortality caused by these agents as public health threats by 2030.

The report was sponsored by the HHS Office of Minority Health, CDC’s Division of Viral Hepatitis and Division of Cancer Prevention and Control, the American Association for the Study of Liver Diseases, Infectious Diseases Society of America and the National Viral Hepatitis Roundtable 

Hepatitis Facts in the U.S.

Viral hepatitis is a leading cause of liver cancer. - Hepatitis C is the most common cause of liver transplant. - An estimated 3.5 million people are living with hepatitis C. - Hepatitis C kills more Americans than any other infectious disease. - An estimated 850,000 people are living with hepatitis B. - About 1,000 babies are born with hepatitis B each year, increasing their risk of liver cancer. - One in four infants infected with hepatitis B at birth will die prematurely.

The report sets out elimination goals for the nation and a practical set of recommendations to scale up current prevention activities and focuses on five areas, which are:

  1. public health information
  2. essential interventions
  3. service delivery
  4. financing elimination
  5. research
Results from phase-one, released in April 2016, concluded that eliminating hepatitis B and C in the United States is feasible, but it will take considerable will and resources.

The phase-two report outlines some key targets for the larger goal of eliminating the public health problem of hepatitis B and hepatitis C in the U.S. Some outstanding targets by 2030 are:

  • A 50% reduction in mortality from hepatitis B compared to 2015.
  • A 90% reduction in incidence of hepatitis C.
  • A 65% reduction in mortality from hepatitis C compared to 2015.

Millions of Americans are living with viral hepatitis, and more than half don’t know they have the virus. Thus, they are at risk for life-threatening liver disease and cancer and unknowingly transmitting the virus to others. It is estimated that 3.5 million people are living with hepatitis C in the United States and 850,000 people are living with hepatitis B.

Viral hepatitis and ethnic minority populations

Viral hepatitis is especially a concern for racial and ethnic minority populations. According to the U.S. Department of Health and Human Services National Viral Hepatitis Action Plan 2017 – 2020:

  • Asian Americans and Pacific Islanders (AAPI) are the racial/ethnic group that is most heavily affected by hepatitis B virus; they comprise about 5% of the U.S. population but comprise about half of all persons living with hepatitis B.
  • An estimated one in 12 AAPIs is living with hepatitis B infection.  However, as many as two of three hepatitis B-infected AAPIs do not know they are infected because they have not been tested.
  • Africans Americans comprise approximately 11% of the U.S. population, but comprise 25% of people in the U.S. with chronic hepatitis C infections.
  • African Americans have higher rates of infection and hepatitis C-related death compared with the overall population.
  • African Americans aged 60 and older are 10 times more likely to be chronically infected with hepatitis C compared to other races. 
  • American Indian and Alaska Native (AI/AN) people are the racial/ethnic group with both the highest rates of acute hepatitis C infection as well as hepatitis C-related deaths. The AI/AN HCV-related death rate is more than double the national rate. Hepatitis C-related hospitalizations among AI/AN people more than tripled from 1995 to 2007.

Click here Exit Disclaimer to go to the National Academies page about the National Strategy for the Elimination of Hepatitis B and C. Exit Disclaimer

To learn more about viral hepatitis, visit the CDC’s page on the disease.

For more information on the data and trends of viral hepatitis in the United States, visit

Last Modified: 10/2/2018 1:13:00 PM